Home
Services
Digital
Technology
RFP Builder
News
About
Careers
Giving
Services
Digital
Technology
RFP Builder
Careers
About us
Get in touch
Case Study

How can Strategic Economic Modelling secure a positive HTA submission?

This case study involves:
Biopharmaceutical
United Kingdom
Landscape Assessment
Stakeholder Interviews
Strategic Recommendations
Economic Modelling

Context

Our client aimed to expand their product range, requiring strategic insights to enhance their cost-effectiveness model (CEM) for a successful UK health technology assessment (HTA) submission.
We were asked to review the current model structures and provide a critique and subsequent strategic recommendations for clinical evidence and economic value optimisation.

Challenges

Linking clinical biomarkers with outcomes affecting Quality Adjusted Life Years (QALYs) and costs is challenging. Advisory board insights and model structure reviews guide go/no-go decisions, but data scarcity hampers comprehensive modelling.

Clinical Biomarker Correlation

Difficulties in linking clinical biomarkers with outcomes that directly influence Quality Adjusted Life Years (QALYs) and associated costs.

Modelling Decision Imperatives

Insightful guidance required for go/no-go modeling decisions, stemming from an advisory board's insights and a thorough review of various model structures.

Data Scarcity

The lack of long-term outcome data, crucial for constructing a comprehensive and effective model.

Key steps

Model Structure Review

FIECON systematically assessed the assumptions underpinning nine different model structures to identify their strengths and weaknesses and analysed their potential to capture the value of the product accurately given the limited data available.

Data Deep Dive

We conducted a critical assessment of existing data, performing an in-depth data deep dive and gap analysis to address uncertainties and data limitations.

Logic Gate Model Creation

FIECON developed a logic gate model which shortlisted four structures, facilitating the decision-making process by providing clear guidance based on clinical expertise.

Key results

Successfully delivered a comprehensive analysis that critically evaluated previous model structures
Illuminating key drivers and challenges that impact the treatment's value
Offered strategic insights and developed an intuitive logic gate model
Significantly reducing uncertainty and paving the way for a positive HTA submission outcome
Get in touch

Relevant resources

Build models faster, with fewer errors
Create economic models in Excel faster, more accurately, and with fewer errors. Our Model Builder ensures consistency across projects, automates calculations, and reduces the risk of human error, giving your teams the confidence to deliver high-quality models in a fraction of the time.
Read more
Interactive BIM
Discover how a best-in-class payer value story combined with an integrated model can drive optimal decision-making.
Read more
Digital Solution
Everything you always wanted to know about JCA
What is JCA?  Is my product eligible? The Joint Clinical Assessment (JCA) for oncology, haematology, and ATMPs will be eligible for assessment from January 12th, 2025...
Read more
Article

Get in touch

Get a completely free, no-obligation opportunity to discuss your needs and see how we can boost your business.
  • Brainstorm solutions to key challenges with experienced team
  • Validate your strategy and value evidence
  • Learn more about FIECON’s products and key areas of expertise and discuss opportunities for collaboration

Your contact details

I would like to
By submitting this form, you confirm that you agree to our website terms of use

Thank you!

We received your details. Someone from our team will contact you soon.
Oops!
Something went wrong while submitting the form.
About us
Services
Get in touch
Privacy Policy
Cookie Policy
Consent Preferences
© Fiecon 2024